What is the appropriate starting dose of atomoxetine (Strattera) for a 60‑kg teenager who is already taking escitalopram?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Starting Dose of Strattera (Atomoxetine)

For a 60-kg teenager already taking escitalopram, start atomoxetine at 0.25 mg/kg/day (approximately 15 mg daily) and increase after a minimum of 3 days to 0.5 mg/kg/day (30 mg daily), then titrate to the target dose of 1.2 mg/kg/day (72 mg daily) over the following weeks.

Dosing Algorithm

Step 1: Adjust for CYP2D6 Inhibition

Since this patient is taking escitalopram (a moderate CYP2D6 inhibitor), the standard FDA dosing must be modified 1:

  • Initial dose: 0.5 mg/kg/day (30 mg/day for 60 kg patient)
  • Wait minimum 3 days before increasing
  • Target dose: 1.2 mg/kg/day (72 mg/day)
  • Maximum dose: 1.4 mg/kg or 100 mg, whichever is less (84 mg for this patient, but practically 80-100 mg)

However, because escitalopram inhibits CYP2D6, start at half the usual initial dose (0.25 mg/kg/day ≈ 15 mg) to minimize early adverse effects, particularly gastrointestinal symptoms and somnolence 1, 2.

Step 2: Titration Schedule

Week 1: 15 mg once daily in the morning

Week 2 (after minimum 3 days): Increase to 30 mg once daily (0.5 mg/kg/day)

Week 3-4: Increase to 60 mg once daily (1.0 mg/kg/day)

Week 5-6: Increase to target of 72 mg once daily (1.2 mg/kg/day)

The FDA label specifies that for children/adolescents up to 70 kg, atomoxetine should be initiated at 0.5 mg/kg/day and increased after a minimum of 3 days to a target of 1.2 mg/kg/day 1. The total daily dose should not exceed 1.4 mg/kg or 100 mg, whichever is less 1.

Step 3: Dosing Frequency Options

Atomoxetine can be administered either:

  • Once daily in the morning (preferred for simplicity and adherence) 1
  • Divided doses (morning and late afternoon/early evening) if tolerability issues arise 1

Research demonstrates that once-daily morning dosing is effective and maintains symptom control throughout the day and into the next morning 3.

Critical Considerations for This Patient

Drug-Drug Interaction with Escitalopram

Escitalopram acts as a CYP2D6 inhibitor, which will increase atomoxetine plasma concentrations. The FDA label explicitly states that in patients taking strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) or in CYP2D6 poor metabolizers, atomoxetine should be initiated at 0.5 mg/kg/day and only increased to 1.2 mg/kg/day if symptoms do not improve after 4 weeks and the initial dose is well-tolerated 1.

While escitalopram is a moderate (not strong) CYP2D6 inhibitor, conservative dosing is warranted. Starting at 0.25 mg/kg/day provides an additional safety margin.

Minimizing Early Adverse Effects

Evidence shows that slower titration with twice-daily dosing reduces early adverse events compared to rapid titration with once-daily dosing 2. Specifically:

  • Fast titration (to 1.2 mg/kg over 3 days) caused higher rates of decreased appetite (14.3% vs 8.0%) and somnolence (14.3% vs 4.2%) in the first 2 weeks 2
  • Slow titration (over 2+ weeks) was better tolerated initially 2

Given the CYP2D6 interaction with escitalopram, use the slower titration approach outlined above.

Monitoring Requirements

Before initiating atomoxetine 4:

  • Obtain personal and family cardiac history (sudden death, cardiovascular symptoms, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome)
  • If risk factors present, obtain ECG and consider cardiology referral
  • Monitor heart rate and blood pressure at baseline and during treatment (atomoxetine increases HR and BP in 5-15% of patients) 4

During treatment:

  • Monitor for suicidal ideation (FDA black box warning) 4
  • Watch for gastrointestinal symptoms and decreased appetite (most common early adverse effects) 4, 5
  • Extremely rarely, monitor for hepatitis symptoms 4

Target Dose Rationale

The 1.2 mg/kg/day target is evidence-based. Clinical trials demonstrated that 3:

  • 1.2 mg/kg/day and 1.8 mg/kg/day were both superior to placebo
  • No additional benefit was seen at 1.8 mg/kg/day compared to 1.2 mg/kg/day 3
  • 0.5 mg/kg/day showed intermediate efficacy but was not superior to placebo 3

Therefore, 1.2 mg/kg/day (72 mg for this 60-kg patient) is the appropriate initial target dose 1, 3.

When to Increase Beyond Target

After 2-4 weeks at the target dose of 1.2 mg/kg/day, if symptoms have not adequately improved and the medication is well-tolerated, the dose may be increased to a maximum of 1.4 mg/kg/day (84 mg) or 100 mg, whichever is less 1. However, there is limited evidence that higher doses provide additional benefit 1, 3.

Common Pitfalls to Avoid

  1. Do not titrate too rapidly in patients on CYP2D6 inhibitors—this increases gastrointestinal side effects and somnolence 2
  2. Do not exceed 100 mg total daily dose in adolescents 1
  3. Do not abruptly discontinue—though atomoxetine can be stopped without tapering, monitor for symptom return 1
  4. Do not open capsules—they must be swallowed whole 1

References

2
Research

Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.

Journal of the American Academy of Child and Adolescent Psychiatry, 2007

Related Questions

What dose should a 33.6 kg child who has been taking 10 mg of atomoxetine (Strattera) for two weeks be increased to?
What is the appropriate dosing regimen of atomoxetine (Strattera) for an 8‑year‑old child?
What is the recommended dosing schedule for Strattera (atomoxetine) for children, adolescents, and adults, including starting dose, titration, maximum dose, and relevant safety considerations?
For an 8‑year‑old child currently taking atomoxetine who still has inadequate symptom control, should the atomoxetine dose be increased, and if so to what target dose, or should another medication be added?
What is the appropriate dosing regimen of atomoxetine for a 13-year-old patient weighing 53 kg?
How should a diabetic patient with hypertension and an LDL cholesterol of 180 mg/dL and total cholesterol of 232 mg/dL be managed?
A 15-year-old male sustained an injury while squatting 175 lb; what is the most likely diagnosis, recommended imaging studies, and appropriate management (operative vs non‑operative) for this injury?
Do these family-history criteria warrant starting colorectal cancer screening before age 45: any first-degree relative with colorectal cancer, colorectal cancer or advanced adenoma in a first-degree relative diagnosed before age 60, colorectal cancer or advanced adenoma in two or more first-degree relatives at any age, or an advanced adenoma in a first-degree relative at any age?
Can an edematous ascitic decompensation raise pro‑BNP (pro‑B‑type natriuretic peptide) levels?
What is the appropriate dose of Benadryl (diphenhydramine) for a 15‑month‑old child weighing 12.15 kg?
In a patient with acute groin and hip pain after squatting 175 lb and a normal plain‑film radiograph showing no fracture, what is the most likely diagnosis and what is the recommended next step in management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.